Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

Marlyn J. Mayo, Julie Parkes, Beverley Adams-Huet, Burton Combes, A. S. Mills, Rodney S. Markin, Raphael Rubin, Donald Wheeler, Melissa Contos, A. B. West, Sandra Saldana, Yonas Getachew, Robert Butsch, Velimir Luketic, Marion Peters, Adrian Di Bisceglie, Nathan Bass, John Lake, Thomas Boyer, Enrique MartinezJames Boyer, Guadalupe Garcia-Tsao, David Barnes, William M. Rosenberg

Research output: Contribution to journalArticle

134 Scopus citations

Abstract

Primary biliary cirrhosis (PBC) is sometimes diagnosed based on a positive antimitochondrial antibody in the appropriate clinical setting without a liver biopsy. Although a liver biopsy can assess the extent of liver fibrosis and provide prognostic information, serum fibrosis markers avoid biopsy complications and sampling error and provide results as a continuous variable, which may be more precise than categorical histological stages. The current study was undertaken to evaluate serum fibrosis markers as predictors of clinical progression in a large cohort of PBC patients. Serial liver biopsy specimens and serum samples were collected every 2 years in 161 PBC subjects for a median of 7.3 years. Clinical progression was defined as development of one or more of the following events: varices, variceal bleed, ascites, encephalopathy, liver transplantation, or liver-related death. Serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and procollagen III aminopeptide were measured and entered into the previously validated enhanced liver fibrosis (ELF) algorithm. The ability of ELF, histological fibrosis, bilirubin, Model for End-Stage Liver Disease (MELD), and Mayo Risk Score to differentiate between individuals who would experience a clinical event from those who would not was evaluated at different time points. Event-free survival was significantly lower in those with high baseline ELF. Each 1-point increase in ELF was associated with a threefold increase in future complications. The prognostic performance of all tests was similar when performed close to the time of the first event. However, at earlier times in the disease process (4 and 6 years before the first event), the prognostic performance of ELF was significantly better than MELD or Mayo R score. Conclusion: The ELF algorithm is a highly accurate noninvasive measure of PBC disease severity that provides useful long-term prognostic information. Copyrtght

Original languageEnglish (US)
Pages (from-to)1549-1557
Number of pages9
JournalHepatology
Volume48
Issue number5
DOIs
StatePublished - Nov 1 2008

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay'. Together they form a unique fingerprint.

  • Cite this

    Mayo, M. J., Parkes, J., Adams-Huet, B., Combes, B., Mills, A. S., Markin, R. S., Rubin, R., Wheeler, D., Contos, M., West, A. B., Saldana, S., Getachew, Y., Butsch, R., Luketic, V., Peters, M., Di Bisceglie, A., Bass, N., Lake, J., Boyer, T., ... Rosenberg, W. M. (2008). Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology, 48(5), 1549-1557. https://doi.org/10.1002/hep.22517